Nitric-Oxide Supplementation for Treatment of Long-Term Complications in Argininosuccinic Aciduria  by Nagamani, Sandesh C.S. et al.
ARTICLE
Nitric-Oxide Supplementation for Treatment of
Long-Term Complications in Argininosuccinic Aciduria
Sandesh C.S. Nagamani,1,10 Philippe M. Campeau,1,10 Oleg A. Shchelochkov,1,10
Muralidhar H. Premkumar,2 Kilian Guse,1 Nicola Brunetti-Pierri,1 Yuqing Chen,1,9 Qin Sun,1
Yaoping Tang,3 Donna Palmer,1 Anilkumar K. Reddy,4 Li Li,5 Timothy C. Slesnick,6 Daniel I. Feig,6
Susan Caudle,6 David Harrison,5 Leonardo Salviati,7 Juan C. Marini,8 Nathan S. Bryan,3 Ayelet Erez,1,11
and Brendan Lee1,9,11,*
Argininosuccinate lyase (ASL) is required for the synthesis and channeling of L-arginine to nitric oxide synthase (NOS) for nitric oxide
(NO) production. Congenital ASL deficiency causes argininosuccinic aciduria (ASA), the second most common urea-cycle disorder, and
leads to deficiency of both ureagenesis and NO production. Subjects with ASA have been reported to develop long-term complications
such as hypertension and neurocognitive deficits despite early initiation of therapy and the absence of documented hyperammonemia.
In order to distinguish the relative contributions of the hepatic urea-cycle defect from those of the NO deficiency to the phenotype, we
performed liver-directed gene therapy in amousemodel of ASA.Whereas the gene therapy corrected the ureagenesis defect, the systemic
hypertension in mice could be corrected by treatment with an exogenous NO source. In an ASA subject with severe hypertension refrac-
tory to antihypertensive medications, monotherapy with NO supplements resulted in the long-term control of hypertension and
a decrease in cardiac hypertrophy. In addition, the NO therapy was associated with an improvement in some neuropsychological param-
eters pertaining to verbal memory and nonverbal problem solving. Our data show that ASA, in addition to being a classical urea-cycle
disorder, is also a model of congenital human NO deficiency and that ASA subjects could potentially benefit from NO supplementation.
Hence, NO supplementation should be investigated for the long-term treatment of this condition.Introduction
The urea cycle consists of a series of enzymatic reactions
that catalyze the conversion of toxic-waste nitrogen to
urea, a nontoxic and excretable nitrogenous compound.
Deficiencies of any of the enzymes of the urea cycle (N-
acetyl glutamate synthase, carbamoyl phosphate synthase
1, ornithine transcarbamylase, argininosuccinate synthase
1 [ASS1], argininosuccinate lyase [ASL], and arginase 1)
result in a group of inborn hepatic-metabolism errors
collectively called urea-cycle disorders (UCDs).1 Subjects
with UCDs typically present with hyperammonemic
episodes that can have neurological consequences. Argini-
nosuccinic aciduria (ASA [MIM 207900]), the second most
common UCD, is caused by the deficiency of ASL (MIM
608310; RefSeq NM_000048.3).1,2 ASA is biochemically
characterized by elevations of argininosuccinic acid
(upstream of the metabolic block) and a deficiency of
arginine (downstream of the metabolic block). In addition
to the hyperammonemia that is common to all UCDs,
subjects with ASA might present with a more complex
clinical phenotype that could include neurocognitive
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even in the absence of documented hyperammonemia,
suggesting that they might result from the functions of
ASL beyond its role in ammonia clearance.3
ASL is the only enzyme that can generate L-arginine.
Most tissues express the enzymes ASS1 and ASL, which
allow for cell-autonomous synthesis of arginine from
citrulline. Arginine is the precursor for the synthesis of bio-
logically important metabolites such as nitric oxide (NO),
polyamines, agmatine, creatine, proline, and glutamate.6
In the presence of ASL deficiency, the secondary deficiency
of arginine could lead to a decreased production of arginine
metabolites. NO has diverse physiological functions
including vascular relaxation, neurogenesis, and neuronal
transmission. There is significant evidence that dysregula-
tion of NO can result in HTN and neurocognitive deficits
in animal models and humans.7–9 We recently showed
that ASL is required for the utilization of endogenous and
exogenous arginine for NO production.10 In the absence
of ASL, a NO-synthesis protein complex is lost, resulting
in the loss of arginine channeling from both intracellular
and extracellular sources to nitric oxide synthase (NOS)
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long-term complications of ASA might result, at least in
part, from the deficiency of NO and that subjects with
ASA might therefore benefit from NO supplementation.Material and Methods
Generation of ASA Mice
The generation of mice hypomorphic for Asl has been described
previously.10 All animal procedures were authorized by the
Institutional Animal Care and Use Committee of Baylor College
of Medicine (BCM). The mice were treated with benzoate
(250 mg/kg per day), L- arginine (100 mg/kg per day), and sodium
nitrite (10 mg/kg per day) in their drinking water, as described
previously, for 5 weeks.10
Helper-Dependent Adenoviral Vector Generation
and Administration
The helper-dependent adenoviral vector (HDAd-gE-mAsl)
contains the liver-restricted ApoE genomic promoter with a liver-
specific enhancer11 driving the expression of mouse Asl. The
helper-dependent adenovirus (HDAd) was produced with the
helper virus AdNG16312 and the 116 producer cell line as
described in detail elsewhere.13,14 Helper-virus contamination
levels were determined as described13 and were found to be
<0.05% for all vector preparations. DNA analyses of HDAd
genomic structure were confirmed for all vectors.13
Immunoblot
Liver sections were snap frozen. The tissue was lysed with a rotor-
stator homogenizer in amild lysis buffer (50mM Tris-HCl [pH7.5],
150 mM NaCl, and 1% Triton-100) with a complete protease-
inhibitor cocktail (Roche, USA). Tissue homogenates were centri-
fuged at 16,000 3 g for 20 min, and the supernatant protein
was quantified with a microBCA assay (Pierce, USA). Immunoblot
analyses were performed with primary antibodies specific to
ASL (Abnova, clone 4C5-1F2) and GAPDH (Sigma clone GAPDH-
71.1, peroxidase-conjugated). After the addition of the secondary
antibody (goat anti-mouse antibody, Abnova), the membranes
were developed with Luminata crescendo luminescent HRP
substrate (Millipore, USA).
Enzyme Activity Assay
All chemicals used were obtained from Sigma-Aldrich (St.Louis,
USA). Protein lysates (20 mg) were incubated with 10mM arginino-
succinic acid in 100 ml of 10 mM Tris-HCl (pH 7.5) with 5 units of
arginase so that ASL activity could be determined. After being incu-
bated for 60 min, the reaction was stopped by being boiled for
5 min, and the urea was quantified with a modified Jung assay.15
Plasma Amino Acids
Plasma amino acids were measured at the CLIA (Clinical Labora-
tory Improvement Amendments)-certified Medical Genetics Labo-
ratories of BCM.16
Stable-Isotope Studies
Mice were restrained, and a tail-vein catheter was inserted. The
tail-vein catheter was connected to syringe infusion pumps
(PHD2000; Harvard Apparatus, Holliston, MA). The primed-con-
tinuous infusion of [guanidino-15N2]-arginine (prime 45 mmol/kg,
continuous 45 mmol/kg per hr), [5-13C,4,4,5,5 2H4]-citrullineThe Am(prime 7 mmol/kg, continuous 7 mmol/kg per hr), and [13C18O]-
urea (prime 100 mmol/kg, continuous 100 mmol/kg per hr) lasted
for 4 hr. We have shown previously that precursors and products
reach a plateau phase within 2 hr.17 Blood samples were collected
at the end of the infusion and were centrifuged at 1500 3 g for
10 min. Plasma was stored at 80C until analysis. The isotopic
enrichments of arginine and citrulline in the plasma were
measured by LC-MS (liquid chromatography-mass spectrometry),
whereas the urea enrichment was measured by GC-MS (gas chro-
matography-mass spectrometry). Fluxes and interconversions
were calculated as previously described.18
NO Studies
Mice were anesthetized with isoflurane. After thoracotomy, a 25G
needle was inserted into the apex of the left ventricle and perfused
with air-equilibrated PBS supplemented with N-ethylmaleimide
(NEM)/EDTA (10/2.5 mM) for a full blood exchange. The right
atrium was cut open so that the blood and buffer would have an
exit port. After 30 s of perfusion, the heart and liver were excised.
Excised tissues were blotted dry on filter paper, weighed, cut into
small pieces and homogenized immediately in ice-cold NEM/
EDTA-containing perfusion buffer. The addition of NEM/EDTA
served the purpose of blocking SH-groups and inhibiting transi-
tion metal-catalyzed transnitrosation reactions, thus preventing
artificial nitrosylation, as well as thiolate and ascorbate-mediated
degradation of endogenous RSNOs.19 Biological specimens har-
vested from anesthetized mice were analyzed for nitroso species
and oxidation products of NO as detailed elsewhere.20,21
BH4 Measurements by High-Pressure Liquid
Chromatography
Tissue biopterins (BH4 and more oxidized species) were measured
by high-pressure liquid chromatography (HPLC) as previously
described.22 Mouse aortae were homogenized with lysis buffer
(50 mM Tris-HCl, 1 mM DTT, and 1 mM EDTA) and oxidized by
exposure to 1% I2 and 2% KI at room temperature for 1 hr under
dark conditions. The reaction was stopped with the addition of
ascorbic acid, and the mixture was centrifuged for 10 min at
12,000 3 g. Biopterins in the supernatant were quantified by
HPLC on a C18 column with fluorescence detection.
Isoprostane Measurement
Urine was collected by bladder aspiration from 30 wild-type (WT)
and ten ASA mice. Blood was collected by retro-orbital bleeding,
and plasma was separated. Isoprostane levels were measured by
ELISA according to the manufacturer’s (Cayman Chemicals,
USA) instructions.
Aortic NOS and Superoxide Studies
The ratio of NOS3 dimers to monomers23 and superoxide levels in
the aortae24 were assessed as previously published.
Invasive Blood-Pressure Measurement
Mice were anesthetized with 1.5% isoflurane (in 100% oxygen),
which was administered at a continuous flow rate of 20 ml/min
(VetEquip, Pleasanton, CA). The neck and xiphoid areas were
shaved, and the anesthetized mouse was placed in a supine posi-
tion in which its paws were taped to electrodes on a tempera-
ture-controlled electrocardiogram (ECG) board. The right carotid
artery of the mouse was isolated and tied off distally, and the prox-
imal end was temporarily occluded. A small cut was made in theerican Journal of Human Genetics 90, 836–846, May 4, 2012 837
artery, and a 1.0 F (0.33 mm) Millar pressure catheter (SPR-100,
Millar Instruments, Houston, TX) was inserted and held in place
with a suture loosely tied over the artery-catheter overlap region.
The proximal end of the artery was then opened, and the catheter
was advanced into the ascending aorta as close as possible to the
aortic root. A second suture was tied over the artery-catheter
overlap so that blood would not leak as the catheter was advanced.
After a minute of stabilization, two segments of blood-pressure
tracings along with their corresponding ECGs were recorded and
stored with the Doppler Signal Processing Workstation (Indus
Instruments, Houston, TX). Systolic, diastolic, and mean pressure
were extracted from the stored aortic pressure files.Wire Myography
Mice were anesthetized with isoflurane. The thoracic and abdom-
inal aortae were exposed by a thoracotomy. A 25G syringe was
inserted into the apex of the left ventricle and was perfused free
of blood with oxygenated Krebs Henseleit buffer. The right atrium
was cut so that the blood would have an exit port. The aorta was
removed and cleaned of all fat and adventitia. The aorta was cut
into 2 mm segments and mounted on a 4 channel wire myograph
(AD Instruments). Vessel rings were maintained in 10 ml organ
baths with oxygenated Krebs buffer (95% O2 and 5% CO2) at
37C. Rings were allowed to equilibrate for 80 min, and the buffer
in each organ bath was changed every 20 min. One gram preten-
sion was placed on each aortic ring (the appropriate starting
tension for optimal vasomotor function was determined in
previous experiments). An 8 channel octal bridge (Powerlab) and
data-acquisition software (Chart version 5.2.2) were used for the
recording of all force measurements. After equilibration for
80 min, 1 mM phenylephrine was added to each ring for submax-
imal contraction. After stabilization, increasing concentrations of
acetylcholine were added to each bath so that the endothelium-
dependent relaxation, which was expressed as percent reversal
of phenylephrine-induced constriction, could be determined.Human Studies
All research procedures were approved by the institutional review
board at Baylor College of Medicine. The subject underwent
continuous monitoring of vitals and hourly BP recordings during
his stay in the hospital. A 24 hr collection of urine was performed,
and urinary nitrite and nitrate levels were assessed both prior to
and 24 hr after initiation of nitrate therapy. A baseline echocardio-
gram was performed before discharge from the hospital and
periodically after treatment. Blood pressure was measured with
Dinamap automated blood-pressure machines (GE healthcare,
USA). Neo40 (Neogenis) is registered as a dietary supplement
with the FDA (reg. no. 3008524085).Neuropsychological Evaluation
Several neuropsychological measures were administered for the
assessment of a variety of cognitive domains, including intelli-
gence, academic achievement, executive functioning, memory,
visual-motor and visual-perceptual skills, fine-motor functioning,
adaptive functioning, and behavioral and emotional functioning.
The evaluation was performed by a board-certified clinical
psychologist at Texas Children’s Hospital, Houston, TX. The
Wechsler Abbreviated Scale of Intelligence (WASI), California
Verbal Learning Test, Children’s Memory Scale, The Test of
Everyday Attention for Children, and Tower of London-Drexel
University measures were administered via standard techniques.838 The American Journal of Human Genetics 90, 836–846, May 4, 2Statistical Analyses
Statistical significance was computed with the Student’s two-tailed
t test, ANOVA, or log-rank tests. A p value < 0.05 was considered
statistically significant. Data are expressed as mean values5 stan-
dard deviation in the bar and line plots in Figures 1–4. The vertical
box plots in Figure 4 depict the median along with the 25th and
75th percentiles, whereas the error bars depict the 5th and 95th
percentiles.Results
Liver-Directed Gene Therapy Results in Long-Term
Correction of the Metabolic Defect in the ASA Mice
To differentiate the physiological consequences of NO
deficiency from the effects of a block in the urea cycle,
we set forth to correct the ureagenesis defect in the ASA
mice10 by gene therapy. We and others have shown
that liver-directed gene transfer with HDAd vectors can
achieve long-term expression extending up to 7 years in
nonhuman primates and can effectively correct a host of
preclinical models of inborn metabolism errors.25 Hence,
we generated a HDAd expressing Asl under the liver-
specific ApoE promoter by using previously described
methods (Figure 1A).11,13 Because ASA mice demonstrate
reduced survival as a result of hyperammonemia, we
treated these mice with triple-therapy consisting of argi-
nine, sodium benzoate, and sodium nitrite from birth as
previously described.10 At 4 weeks of life, we randomized
the mice so they would receive either gene therapy (GT)
or a placebo, and we withdrew triple-therapy at 5 weeks
of life to assess the long-term effects of GT alone. The
GT-treated ASA mice showed hepatic ASL protein levels
comparable to those of WT mice; these protein levels
resulted in the normalization of their hepatic ASL enzyme
activity (Figures 1B and 1C). The plasma amino acid pro-
file and growth normalized, and survival was extended
beyond 5 months (Figures 1D–1F). These results show
that we were able to correct the ureagenesis defect in the
liver by using GT.
Hypertension and Persistent NO Deficiency in the
Vasculature Despite Correction of the Metabolic
Defect in the ASA Mice
Despite the long-term correction of the metabolic defect in
the liver, the GT-treated ASA mice continued to have
significant hypertension as measured by both tail cuff
and indwelling carotid catheters (Figure 2A). To validate
that the hypertension is associated with NO deficiency,
we compared tissue levels of nitrosothiols (RSNO; a
biomarker of NO)26 in GT-treated ASA mice to those of
their WT littermates. Whereas the RSNO levels were signif-
icantly higher in the GT-treated mouse livers, the RSNO
levels in the hearts were significantly lower than in WT
mice (Figure 2B). This implies that normalization of
hepatic ASL levels by liver-directed GT was associated
with increased NO production in the liver, whereas other
tissues that still lacked ASL had decreased amounts of012
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Figure 1. Liver-Directed Gene Transfer Corrects the Metabolic Defect in ASA Mice
A total of 23 ASAmice were randomized to receive either gene therapy (GT) or a placebo. Triple therapy was withdrawn at 5 weeks of life
so that the long-term effects of GT alone could be assessed. The error bars in the bar and line graphs depict standard deviation.
(A) Structure of the helper-dependent adenoviral construct with the murine Asl cDNA under the regulation of the ApoE promoter. The
following abbreviations are used: ITR, inverted terminal repeat; WPRE, Woodchuck hepatitis virus posttranscriptional regulatory
element; LCR, locus control region; and GhpA, growth hormone polyA.
(B) A representative immunoblot of liver compares the ASL protein levels between three WT mice, three placebo-treated ASA mice, and
three GT-treated ASA mice 2 weeks after GT. Densitometry quantification shows the correction of ASL protein levels. Asterisks indicate
p < 0.05. The following abbreviation is used: n.s., not significant.
(C) Representative ASL enzyme activity. Compared with untreated mice (n ¼ 3), ASA GT-treated mice (n ¼ 3) show correction of
enzymatic activity in the liver. Asterisks indicate p < 0.05. The following abbreviation is used: n.s., not significant.
(D) Amino acid profile of ASAmice (n¼ 4) versus GT-treated ASAmice (n¼ 4) at 8 weeks of age showing biochemical correction. Asterisks
indicate p < 0.05. The following abbreviations are used: CIT, Citrulline; and ASA, argininosuccinic acid.
(E) GT-treated ASA mice (n ¼ 15) demonstrate significantly better growth than those treated with the placebo (n ¼ 8). Asterisks indicate
p < 0.05.
(F) Kaplan-Meier survival curve. GT-treated ASA mice (n ¼ 15) show 100% survival by week 16 of life, whereas all placebo-treated ASA
mice (n ¼ 8) expired by day 103. Asterisks indicate p < 0.001.NO, supporting a tissue-specific ASL requirement for NO
production.
To evaluate whether this decreased NO production in
the vascular tissue is involved in the pathogenesis of
hypertension, we performed classic aortic-ring experi-
ments and examined the relaxation response to L-arginine
and NO donors. In this experiment, vessel rings from
mouse aortae were preconstricted by exposure to phenyl-
ephrine, an alpha-adrenergic agonist that causes vasocon-
striction. The rings were then exposed to increasingThe Amconcentrations of acetylcholine (Ach), which causes
vasodilatation as a result of the release of NO generated
by NOS3 of the vascular endothelium.27 The aortae from
WT mice showed a significant relaxation, whereas the
GT-treated ASA mice showed a persistent lack of relaxation
in response to either Ach or L-arginine (Figures 2C and
2D). However, the aortic rings of GT-treated mice showed
a definitive relaxation in response to a NO donor, sodium
nitroprusside (SNP) (Figure 2D). This ex vivo experiment
demonstrates that the impaired vascular relaxationerican Journal of Human Genetics 90, 836–846, May 4, 2012 839
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Figure 2. Tissue-Specific NO Deficiency and Hypertension Despite Correction of the Metabolic Defect in the Liver of GT-Treated ASA
Mice
(A) Invasive BP measurements at age 12–14 weeks (n ¼ 3 per group) showed that GT-treated ASAmice had elevated systolic and diastolic
BPs when they were compared with WT mice. Asterisks indicate p < 0.05.
(B) RSNO levels measured in liver and hearts of six GT-treated ASA mice and sevenWTmice showed significantly higher RSNO levels in
the livers and significantly lower levels in the hearts of the GT-treated ASA mice. Asterisks indicate p < 0.05.
(C) Preconstricted WT aortic rings relaxed in a concentration-dependent fashion with acetylcholine (Ach) treatment beginning at
a concentration of 10 nM, wheras aortic rings from GT-treated ASA mice were unresponsive to Ach. Data points are derived from
measurements from four segments of each aorta in three WT and three GT-treated mice ASA mice. The asterisk indicates p < 0.05.
(D) Representative tracing of aortic-ring isometric tension in GT-treated ASA mice shows no relaxation in response to Ach or L-arginine,
whereas NO donor sodium nitroprusside (SNP) leads to a significant relaxation. Three aortic rings from each mouse aorta were used for
analysis.
(E) In vivo vascular response to nitrite infusion in 4-month-old GT-treated ASAmice (n¼ 3) shows normalization of BP. Asterisks indicate
p < 0.05. The following abbreviation is used: n.s., not significant.
The error bars in the bar and line graphs depict standard deviation.resulted from the inability of the vasculature to generate
NO from arginine in a NOS-dependent manner and that
a NOS-independent NO source could rescue the deficiency.
To confirm this finding in vivo, we infused the GT-treated
ASA mice with intravenous sodium nitrite, a NO source,
and the fact that this treatment significantly decreased
the mean arterial pressure corroborates the results of the
aortic-ring experiments (Figure 2E).
Lack of L-Arginine-Substrate Availability to NOS Due
to ASL Deficiency Is the Primary Cause of Decreased
NO Production in the Vasculature
We have previously reported that the ASA mice were
hypertensive andNOdeficient.10 Because a lack of arginine
substrate can lead to the uncoupling of NOS3 (eNOS) and
result in enhanced free-radical generation along with
decreased NO production,28,29 we measured the ratio of
NOS3 dimers to monomers as a reflection of NOS3-840 The American Journal of Human Genetics 90, 836–846, May 4, 2coupling status in the aortae of ASA mice. Indeed,
compared with theirWT littermates, ASAmice had a signif-
icant reduction in this ratio, suggesting that the lack of ASL
is associated with the uncoupling of NOS3 (Figure 3A). To
evaluate whether NOS3 uncoupling was also associated
with increased free-radical production, we measured iso-
prostane levels (a marker of oxidative stress) in plasma
and urine. The ASA mice had significantly higher levels
of isoprostane than did their WT littermates (Figure 3B).
To specifically assess the free-radical production at the level
of vascular tissues, we measured superoxide levels in
murine aortae and found that the levels in ASA mice
were significantly higher than those in their WT litter-
mates (Figure 3C). Together, these data demonstrate
increased free-radical production in the ASA mice.
In the context of increased free-radical production, NO
deficiency can result either from NOS uncoupling or
from its scavenging by free radicals. To evaluate whether012
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Figure 3. NOS Uncoupling and Increased Free-
Radical Levels in ASA Mice
(A) Immunoblot and densitometric quantifica-
tion from the aortae of three ASA mice and three
WT mice show a decrease in the active dimer
form in the ASA mice, supporting NOS3 (eNOS)
uncoupling. The asterisk indicates p < 0.05.
(B) Isoprostane levels, a marker of free-radical
production, are significantly increased in ASA
mice. Asterisks indicate p < 0.05.
(C) Compared to those ofWTmice (n¼ 5), super-
oxide levels from the aortae of ASA mice (n ¼ 5)
are elevated. The asterisk indicates p < 0.05.
(D) In vivo isotope measurement of the transfer
of the guanidino-nitrogen from 15N2-arginine to
15N-citrulline, a marker of NO flux, is decreased
in the GT-treated ASA mice (n ¼ 5 per group).
The asterisk indicates p < 0.05.
(E) Compared to those of WT mice, the BH4/BH2
ratios in the aortae of ASA hypomorphic mice
and GT-treated ASA hypomorphic mice are not
significantly different. The following abbrevia-
tion is used: n.s., not significant.
The error bars depict standard deviation.decreased NO production or increased NO scavenging
contributed to the NO deficiency, we performed stable-
isotope studies in the GT-treated ASA mice. Our results
show that the transfer of nitrogen from guanidino-
[15N2]-arginine to ureido-[
15N]-citrulline, a dynamic
marker of NO production, was significantly decreased in
the GT-treated ASAmice (Figure 3D). This finding supports
the hypothesis that the decreased NO production in ASL
deficiency predominantly results from the decreased
oxidation of arginine to citrulline.
Because BH4 availability is a known regulator of NOS3
activity and enzymatic coupling,30 we further assessed
the impact of ASL loss of function on BH4 availability
and metabolism. We measured the ratio of BH4 levels to
BH2 levels in the aortae of ASA mice, GT-treated ASA
mice, and their corresponding WT littermates. We found
that the BH4/BH2 ratio in ASA and GT-treated ASA mice
was no different from that of the WT mice, suggesting
that NOS3 uncoupling was not caused by perturbation of
BH4 (Figure 3E). When free radicals are the primary cause
of vascular injury, the BH4/BH2 ratio is usually dramatically
reduced as a result of the oxidation of BH4 to BH2.
30 All
together, the lack of evidence of BH4 deficiency in bothThe American Journal ofthe ASA and the GT-treated ASA mice, the
decreased in vivo NO production as
measured by the isotope flux studies, and
the response of the HTN to nitrite supple-
mentation indicate that decreased argi-
nine-substrate availability is the primary
explanation for NOS uncoupling. As a result
of NOS uncoupling in ASL deficiency,
there is a decrease in NO production along
with a secondary increase in free-radical
production.In summary, these results suggest that the liver-targeted
GT rescues the ureagenesis defect in the liver but not the
tissue-specific ASL requirement for the utilization of argi-
nine in NO production. More importantly, our results
confirm that the vascular dysfunction seen with ASL defi-
ciency is independent of the metabolic defect in the urea
cycle, is directly associated with NO deficiency in the
vasculature, and can be rescued by a NOS-independent
NO source in vivo.
NO Supplementation for Treatment of Hypertension
in a Human Subject with ASA
HTN has been anecdotally reported as a complication in
human ASA subjects.3,31 We have previously shown
a significantly decreased NOS-dependent flow-mediated
vasodilatation in ASA subjects while their vasodilatory
response to a NOS-independent NO donor is normal.10
These results suggest that in ASL deficiency, the cellular
signaling events downstream of NO are intact and that
the vascular pathology and hypertension are probably
due to a deficiency of NO in the vasculature.
One of the ASA subjects under our clinical care pro-
vided us with an opportunity to translate our findingsHuman Genetics 90, 836–846, May 4, 2012 841
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Figure 4. Clinical Treatment with NO Supplements Corrects Hypertension in a Subject with ASA
The vertical box plots depict the 25th and 75th percentiles along withmedian blood-pressure values at various time points. The error bars
depict the 5th and 95th percentiles. The red shaded area depicts the 50th and 90th blood percentiles for age and stature. Median BP values
that were above the 90th percentile prior to initiation of organic-nitrate therapy in spite of combination antihypertensive therapy (left
panel) show sustained normalization with NO supplementation therapy; this sustained normalization allowed for the withdrawal of all
other antihypertensive medications (middle and right panels).in a human therapeutic context. This subject was diag-
nosed with ASA at 3 years of age and with idiopathic
HTN at 5 years of age. His systolic and diastolic BPs
were repeatedly above the 95th percentile for his age and
stature for a period of over 10 years. This was in the
setting of normal levels of plasma arginine due to con-
tinuous supplementation with L-arginine, a standard
therapy for the prevention of hyperammonemia (data
not shown). Evaluations for secondary causes of hyper-
tension, including measurements of serum electrolytes,
renal function, and plasma-renin and aldosterone levels
and a renal-arterial duplex ultrasonography, were un-
remarkable (Table 1). Dietary salt restriction, thiazide
diuretics, and enalapril were sequentially introduced
but failed to normalize his BP. The subject was started
on treatment with propranolol, nifedipine, and subse-
quently, amlodipine (Figure 4, left panel). In spite of
adequate dosing and compliance (evidenced by signifi-
cant bradycardia), the control of his hypertension
remained suboptimal. The median systolic and diastolic
BPs ranged between 130–140 and 75–90 mm of Hg,842 The American Journal of Human Genetics 90, 836–846, May 4, 2respectively, which were both above the 95th percentile
for his age and stature (Figure 4, left panel).
Clinical mutation analysis revealed that the subject had
compound heterozygous mutations in ASL: c.857A>G
(p.Gln286Arg) and c.557G>A (p.Arg186Gln). Both muta-
tions have been reported to be pathogenic.32,33 Molecular
modeling of the ASL tetrameric protein with these two
alterations predicts that at least one active catalytic site is
reconstituted and thus allows for partial enzymatic activity
(Figure S1A, available online). Indeed, study of this
subject’s fibroblasts showed residual protein and enzyme
activity consistent with a hypomorphic state (Figures S1B
and S1C).
At the age of 15 years, this subject presented with hyper-
tensive urgency and had a systolic BP between 160–
170 mm of Hg. Because of the ASL requirement for
systemic NO production, the resemblance of his biochem-
ical phenotype to the ASA mouse model, and the response
to sodium-nitrite treatment in the ASA mouse, we hypoth-
esized that the hypertension in this subject was probably
due to systemic NO deficiency and that treatment with012
Table 1. Blood and Urine Analysis before and after Initiation of
NO Supplementation
Before NO
Supplementation
After NO
Supplementation
Plasma renin normal normal
Plasma aldosterone normal normal
Plasma brain natriuretic
peptide (BNP)
not tested normal
Urinary protein (mg/24 h,
normal 28–141)
257 (elevated) 51 (normal)
Urinary nitrite (mg/ml,
normal is not detectable)
not detectable 17 (elevated)
Urinary nitrate (mg/ml,
normal is 0–124 mg/ml)
140 (elevated) 480 (elevated)
Urinanalysis showed a decrease in protein excretion together with increased
urinary nitrate, as would be expected from therapy.
Table 2. Echocardiogram Measurements before and after
Initiation of NO Supplementation
Left Ventricle (LV)
Parameters
Before NO
Supplementation
(Z Score)
After NO
Supplementation
(Z Score)
LV diastolic septal thickness 2.26 1.33
LV diastolic dimension 2.10 0.36
LV diastolic wall thickness 3.59 2.24
LV systolic septal thickness 4.08 1.94
LV systolic dimension 2.08 0.67
LV systolic wall thickness 3.01 1.53
LV dimensions were measured before and 5 months after initiation of NO
supplementation. All parameters demonstrate normalization or improvement.a NOS-independent NO source would be beneficial. Hence,
over a 4 day period, the subject was initiated on divided
doses of an organic nitrate, isosorbide dinitrate (ISDN)
(starting at 0.2 mg/kg per day and titrated to 0.6 mg/kg
per day). At the same time, amlodipine was discontinued,
and propranolol was weaned to 0.6 mg/kg per day. The
subject’s systolic, diastolic, and mean arterial pressures
showed dramatic normalization during this short period
of time (Figure S2). Concurrent with the weaning of his
b-blocker (propranolol), the subject’s bradycardia resolved
(Figure S2).
An echocardiogram prior to the patient’s discharge from
the hospital showed mild concentric left ventricular
hypertrophy (LVH) with normal left ventricular systolic
function (Table 2). During the subsequent 3 months, the
mean BP was 120/74 mm Hg (standard error of 0.89 and
0.72 for systolic and diastolic pressures, respectively; n ¼
125 readings), thus allowing for the discontinuation of
the remaining antihypertensive medications. On mono-
therapy with ISDN, the subject’s BP remained within
normal limits for 9months. An echocardiogram performed
after 5 months of ISDN treatment showed an improve-
ment in left ventricular parameters and mild residual
hypertrophy (Table 2). In addition, urinanalysis showed
a decrease in proteinuria together with increased urinary
nitrate, as would be expected from such therapy (Table 1).
After 9 months of treatment with ISDN, the subject’s BP
started to trend toward the upper limits of normal values
(Figure 4, middle panel). The loss of efficacy of therapy
with nitrate might be due to acquired tolerance resulting
from decreased bioconversion to NO34 and is a common
effect of chronic organic-nitrate treatment. Hence, we
started treatment with a uniquely formulated dietary
supplement that contains sodium nitrite together with
natural products that have nitrite-reductase activity to
enhance direct conversion to NO (Neogenis Labs). Indeed,
this direct NO supplementation normalized the subject’s
BP for an additional 12 months (Figure 4, right panel).
Our results suggest that NO deficiency was an importantThe Amcontributor to the hypertension in this ASA subject, and
treatment with a NOS-independent NO source therefore
resulted in the normalization of his BP.
NO Supplementation is Associated with Improvement
in Neurocognitive Measures in a Human Subject
with ASA
Subjects with ASA have an increased incidence of atten-
tion-deficit hyperactivity disorder, developmental dis-
ability, and seizures when they are compared with subjects
diagnosed with other UCDs.2 Recent long-term-outcome
studies in subjects with ASA show that these neurobeha-
vioral abnormalities can be observed even in subjects
withoutmetabolic decompensations.4 This raises the inter-
esting question of whether the deficiency of arginine
metabolites, specifically NO, could partially contribute to
these phenotypes. Hence, in this ASA subject who was
treated with NO supplementation, we performed neuro-
psychological evaluations before and after treatment to
evaluate whether NO therapy was associated with any
changes in the neurocognitive parameters. We adminis-
tered several neuropsychological tests to assess a variety
of cognitive domains, including intelligence, academic
achievement, executive functioning, memory, visual-
motor and visual-perceptual skills, fine-motor functioning,
adaptive functioning, and behavioral and emotional func-
tioning. Commonly used measures that have established
validity and reliability were selected (Figure 5). The
subject’s overall intelligence quotient (IQ) as measured
by the WASI remained steadily in the impaired range
(full IQ ¼ 62, performance IQ ¼ 72, and verbal IQ ¼ 55)
and did not show any significant changes with treatment.
However, there were marked improvements in the areas
of verbal memory and significant gains in the area of
nonverbal problem solving. Improvements were noted in
problem-solving efficiency, and there was a decrease in
rule-breaking behavior (Figures 5A–5C). The subject’s
tendency to engage in impulsive or intrusive behavior
decreased in the list-learning task, in which the number
of intrusion responses decreased significantly (Figure 5A).erican Journal of Human Genetics 90, 836–846, May 4, 2012 843
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Figure 5. Neuropsychological Testing Results
before and after NO Supplementation
(A) California Verbal Learning Test-Children’s
Version. Raw scores show a significant decrease
in intrusions and a mild increase in the other
parameters. Aside from the intrusion score,
higher scores on the test indicate improved
performance.
(B) Children’s Memory Scale: Stories Subtest
Scaled Scores show improvement in scores after
treatment.
(C) Tower of London-Drexel University mea-
surements show significant improvement in
nonverbal problem solving with treatment
(higher scores indicate poorer performance).Discussion
ASA, the second most common urea cycle disorder, has
a unique phenotype with features that are not observed
in subjects with other defects of ureagenesis. Some of
the distinguishing features include potentially severe
hepatic disease, increased neurocognitive deficiencies,
systemic HTN, and trichorrhexis nodosa (coarse and
brittle hair). The present standard therapies, such as die-
tary protein restriction, arginine therapy, and nitrogen-
scavenging therapy with either benzoate or phenylbuty-
rate, for subjects with ASA are focused on treating the
defect in hepatic ureagenesis. Although this approach is
effective in preventing episodes of hyperammonemia, it
does not prevent the long-term complications.4,35 The
facts that these complications can be observed in subjects
with no significant hyperammonemic episodes and that
they occur despite early initiation of L-arginine therapy
imply that they might be caused by a cell-autonomous
loss of ASL function rather than a block in ureagenesis.
Dissecting the phenotypic consequences of ASL loss in
the liver and comparing them with those of ASL loss in
other tissues would not only help us to understand the
molecular pathogenesis of these complications but could844 The American Journal of Human Genetics 90, 836–846, May 4, 2012also lead to optimization of the treatment
in subjects with ASA.
In this study, we report that treatment
with a liver-specific HDAd vector encoding
Asl corrects the hepatic urea-cycle defect
and normalizes growth and survival in
ASA mice. However, the GT-treated ASA
mice remain hypertensive because of
a tissue-specific ASL requirement for NOS-
dependent NO production in the vascula-
ture. We show that these GT-treated ASA
mice respond to NO supplementation
with the normalization of their vessel
relaxation ex vivo and of their BPs in vivo.
These preclinical studies show that HTN
is independent of the ureagenesis defect
and can be corrected with the use of NOS-
independent NO supplementation. In addi-tion, we show that although there is evidence of increased
free-radical production resulting from NOS uncoupling in
ASA mice, the decreased channeling of arginine to NO
production is the primary cause of the NO deficiency.
Importantly, as a proof of principle, we show the trans-
latability of our findings in the human context. We show
that treatment with a NO source leads to sustained normal-
ization of BP in an ASA subject when all other standard
antihypertensive treatments had failed over a period of
10 years. Nitrates are not a standard therapy for the treat-
ment of hypertension in the general population because
of the availability of more potent antihypertensivemedica-
tions. Few studies have shown the utility of nitrates for the
treatment of isolated systolic hypertension in the elderly
population36,37 when they are combined with other anti-
hypertensive medications. Notably, monotherapy with
nitrates has not been used as a modality for treatment of
hypertension in either the pediatric or the adult popula-
tions. The hypertension in ASA is associated with an
inherent deficiency of systemic NO,10 and hence, the
response to monotherapy with NO supplementation was
rapid in the subject with ASA. The development of toler-
ance to nitrates is a common finding with prolonged use
of the medication,38 and we therefore substituted the
organic nitrate with a specially formulated inorganic
nitrite supplement that resulted in the sustained control
of BP. Although the data regarding the response of BP
along with the improvement of cardiac hypertrophy are
encouraging, they are best considered as preliminary
observations from a single subject. Evaluating whether
our observations can be generalized to other subjects
with ASA would require a randomized controlled trial.
Intriguingly, we observed that NO-supplementation
therapy in this individual also brought about improve-
ments in some neurobehavioral parameters pertaining to
verbal memory, nonverbal problem solving, and impulsive
and intrusive behavior. Although it is possible that at
least some of the apparent improvement in performance
reflects practice effects, the long 16 month intertest inter-
val between evaluations makes this possibility less likely.
Even though abnormalities in metabolites that are syn-
thesized from arginine, such as creatinine and glutamate,
free-radical-mediated damage, and accumulation of toxic
substances like guanidinosuccinic acid might also con-
tribute to the pathogenesis of the neurological complica-
tions, our results support a salutary effect with NO supple-
mentation. These descriptive results, although interesting,
constitute observations from a single subject and do not
prove that the improvements were due to the NO supple-
mentation. However, our results support the contention
that the investigation of NO supplementation in ASA
subjects should be performed in a systematic manner.
Our data show that ASA is a human genetic model of
NO deficiency, and subjects might therefore benefit from
long-term NO supplementation. These results, together
with our previous report,10 also suggest that there might
be specific genotype-phenotype correlations. Hence, the
prevalence andmagnitude of NO deficiency and the result-
ing phenotypic severity in this population will probably
vary depending on the differential effects of alterations
to the catalytic activity and structural integrity of ASL.
This might be clinically reflected in the incomplete pene-
trance of hypertension and neurological abnormalities
seen in ASA subjects. Ultimately, these data further support
the literature regarding the fact that the nitrate-nitrite-NO
pathway is a viable target for NO restoration,39 and they
call for the continued exploration of NO supplementation
in this disease in a randomized controlled setting and in-
depth correlation with the genotype. Moreover, manipu-
lating ASL could be a relevant therapeutic target for other
diseases for which NO has been shown to play a role in
disease pathogenesis.
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